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Abstract
AIM: To investigate the effect of prednisolone, a 
synthetic glucocorticoid used in inflammatory diseases, 
on the growth of cultured osteosarcoma cells.
 
METHODS: Two osteosarcoma cell lines with different 
degree of differentiation were used. SaOS2 show a 
rather mature phenotype, while U2OS are negative for 
almost all osteoblastic markers. The cells were exposed 
to different concentrations of prednisolone (1-9 µmol/L) 
with or without antioxidants or the inhibitor of inducible 
nitric oxide synthase (iNOS) l-N6-(iminoethyl)-lysine-HCl 
(L-NIL). Cell growth was assessed by counting viable 
cells. The production of nitric oxide (NO) was measured 
in the conditioned media by the Griess method. The 
production of reactive oxygen species was quantified 
using 2’-7’-dichlorofluorescein diacetate. Western blot 
with specific antibodies against NOSs was performed 
on cell extracts.
 
RESULTS: Prednisolone inhibited SaOS2 cell growth in 
a dose dependent manner. No significant effects were 
observed in U2OS. The inhibition of SaOS2 growth is 
not due to oxidative stress, because antioxidants do 
not rescue cell proliferation. Since high concentrations 
of NO inhibit bone formation, we also measured NO 
and found it induced in SaOS2, but not in U2OS, 
exposed to prednisolone, because of the upregulation 
of iNOS as detected by western blot. Therefore, we 
treated SaOS2 with prednisolone in the presence or 
in the absence of L-NIL. L-NIL prevented NO release 
induced by prednisolone at all the concentrations apart 
from 9 µmol/L. At the same concentrations, we found 
that L-NIL rescued SaOS2 growth after exposure to 
prednisolone. In U2OS cells, prednisolone did not induce 
NO production nor affected cell growth. All together, 
these data indicate that a link exists between increased 
amounts of NO and growth inhibition in response to 
prednisolone in SaOS2.
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CONCLUSION: Prednisolone inhibited SaOS2 prolife-
ration by increasing the release of NO through the 
upregulation of iNOS, while no effect was exerted on 
U2OS.
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Core tip: Since prednisolone, a widely used synthetic 
glucocorticoid, inhibits osteoblast proliferation, we 
evaluated its effects on osteosarcoma cells. In particular, 
we used two osteoblastic osteosarcoma cell lines with 
different degree of differentiation, i.e. , SaOS2, which 
have a rather mature phenotype, and U2OS, which are 
less differentiated. We found that prednisolone inhibited 
SaOS2 proliferation by increasing the release of nitric 
oxide (NO) through the upregulation of inducible NO 
synthase (iNOS). Indeed, pharmacological inhibition 
with the iNOS inhibitor l-N6-(iminoethyl)-lysine-HCl 
restored the normal proliferation rate of the SaOS2. 
On the contrary, prednisolone did not modulate NO 
production nor cell growth in U2OS.
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INTRODUCTION
Osteosarcomas are aggressive primary malignant 
tumors of the bone characterized by the deposition of 
immature bone by the neoplastic cells which most likely 
arise from mesenchymal stem cells. Osteosarcomas 
mostly affect teenagers and frequently metastasize. 
Nowadays, systemic multidrug chemotherapy and 
surgery are successful in 60%-70% of patients. There-
fore, novel approaches are foreseen.  
Since glucocorticoids participate to the regulation of 
survival, differentiation, and proliferation of many cell 
types, including osteoblasts and bone mesenchymal 
stem cells[1-3], we asked whether glucocorticoids might 
control the growth of osteosarcoma cells. Glucocorticoids 
act by binding their cognate receptor which functions as 
a hormone-regulated transcription factor. In addition, 
glucocorticoids interact with transcription factors such 
as AP1 and nuclear factor kappa B (NF-κB) and inhibit 
their activity. They can also modulate some intra-
cellular signalling pathways, one of which is the MAP 
kinase cascade. Because of their effects on cell cycle 
progression and apoptosis[4], they are also used in the 
treatment of lymphoid malignancy and of some solid 
cancers[5,6]. 
In this study, we evaluate the effect of prednisolone, 
a synthetic glucocorticoid widely used to treat inflam-
matory diseases, on cultured osteosarcoma cells. It is 
well known that cultured neoplastic cells have been the 
basis of cancer biology and the chase to identify drug 
treatments[7]. Two human osteosarcoma cell lines are 
particularly intriguing, i.e., SaOS2 and U2OS, which are 
among the first generated cell lines used for anticancer 
research[8]. U2OS were derived from a moderately 
differentiated sarcoma of a 15-year-old girl, and SaOS2 
from an osteogenic sarcoma of an 11-year-old girl. 
SaOS2 are relatively resistant to drugs because of the 
mutation of major oncosuppressors, i.e., p53 and Rb[9], 
which are functional in U2OS. While SaOS2 show a 
mature phenotype, U2OS are negative for almost all 
osteoblastic markers but positive for cartilage markers 
like collagen Ⅱ, Ⅸ and Ⅹ and for type Ⅳ collagen, 
which is only expressed in very early differentiation 
stages but not by mature osteoblasts. These two cell 
lines were selected for this study because of their 
different degree of differentiation and gene expression. 
MATERIALS AND METHODS
Cell culture
SaOS2 and U2OS (American Type Culture Collection) 
were cultured in DMEM containing 10% fetal bovine 
serum. Proliferation assays were performed on cells at 
low density (7000/cm2) with different concentrations 
of prednisolone. After trypsinization and staining with 
trypan blue solution (0.4%), the viable cells were 
counted. In some experiments cells were exposed 
to apocynin (10 µg/mL), trolox (40 µmol/L), or l-N6-
(iminoethyl)-lysine-HCl (L-NIL) (100 µmol/L), a selective 
inhibitor of inducible nitric oxide synthase (iNOS).
 
Reactive oxygen species evaluation
Intracellular oxidative stress was quantified using 
2’-7’-dichlorofluorescein diacetate (DCFH). Cells were 
seeded into black bottomed 96 plates (Greiner Bio-
One) and 24 h later exposed for 30 min to different 
concentrations of prednisolone dissolved in a 20 µmol/L 
DCFH solution. The rate of intracellular oxidative stress 
was evaluated by monitoring the emission at 529 nm of 
the DCFH dye using Promega Glomax Multi Detection 
System[10]. Data are shown as the mean of three 
independent experiments in triplicate ± SD. H2O2 (50 
µmol/L) was used as a positive control.
 
NOS activity
NOS activity was measured in the conditioned media by 
the Griess method as described[11]. Data are shown as 
the mean of four independent experiments in triplicate 
± SD. 
 
Western blot analysis
Western blot was performed using anti-iNOS, total 
endothelial nitric oxide synthase (eNOS) and p-eNOSSer1177 
antibodies (Cell Signalling Technology) followed by 
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incubation with secondary antibodies labelled with 
horseradish peroxidase (GE Healthcare). Anti-actin 
antibodies (Sigma-Aldrich) were used to show that 
equal amounts of proteins were loaded per lane. The 
SuperSignal chemiluminescence kit (Thermo Fisher 
Scientific) was utilized to detect immunoreactive proteins. 
Densitometry was performed using ImageJ software and 
results are shown as the mean ± SD of three separate 
experiments. A representative blot is shown.
 
Statistical analysis
Statistical significance was determined using the 
student’s t test and set at P values less than 0.05. In the 
figures aP < 0.05; bP < 0.01; dP < 0.001.
RESULTS
Prednisolone inhibits SaOS2 cell proliferation
SaOS2 were cultured in media containing different 
concentrations of prednisolone and counted after 4 
d. Figure 1A shows that prednisolone inhibits SaOS2 
cell growth in a dose dependent manner. No effect is 
observed in cells treated with 1 µmol/L prednisolone, 
while growth inhibition is significant with 3, 6, and 9 
µmol/L. Similar results were obtained when the MTT 
assay was used (data not shown). Under the same 
experimental conditions U2OS were less sensitive to
prednisolone than SaOS2 since a modest growth inhibi-
tion was observed only with 9 µmol/L of prednisolone 
(Figure 1B). 
We focused on SaOS2 to understand the mechanisms 
underlying the inhibitory effect of prednisolone. Since 
the detrimental effects of glucocorticoids in osteoblasts 
are mediated by the induction of oxidative stress[12], we 
measured intracellular reactive oxygen species (ROS) 
by DCFH fluorescence in SaOS2. Prednisolone did not 
significantly affect the basal levels of DCFH-detectable 
ROS (Figure 2A). Accordingly, antioxidants, i.e., 
apocynin, a nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase inhibitor, and trolox, a water soluble 
analog of α-tocopherol, did not prevent growth inhibition 
by prednisolone (Figure 2B). 
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Figure 2  Prednisolone does not induce the formation of reactive oxygen species and antioxidants do not prevent growth inhibition. A: SaOS2 cells were 
treated with various concentrations of prednisolone. H2O2 was used as positive control. Reactive oxygen species generation was measured. Data are shown as the 
mean of three separate experiments ± SD. P value was calculated vs untreated cells and found not significant; B: SaOS2 cells were treated with apocynin (10 µg/mL) 
or trolox (40 µmol/L) in the presence of prednisolone (Prd). Viable cells were counted after 96 h. Results are shown as the mean of three separate experiments ± SD. 
CTR: Control. 
Figure 1  Prednisolone inhibits the growth of SaOS2 but not of U2OS. A: Viable SaOS2 cells were counted after 4 d in the presence of different concentrations of 
prednisolone (aP < 0.05; bP < 0.01); B: Viable U2OS cells were treated as above and counted after 96 h (aP < 0.05). Results are shown as the mean of three separate 
experiments ± SD. CTR: Control.
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or in the absence of the iNOS inhibitor L-NIL (100 µmol/L) 
for 96 h. Figure 4A shows that L-NIL (100 µmol/L) 
prevented NO release induced by prednisolone up to 6 
µmol/L, but not at 9 µmol/L. We then counted the cells 
and found that L-NIL prevents prednisolone-dependent 
growth inhibition up to 6 µmol/L (Figure 4B). 
DISCUSSION
High levels of glucocorticoids impact on the generation 
and lifespan of osteoblasts[15]. In humans, prednisolone, 
even at low doses[16], causes significant bone loss and 
increases the risk of fractures through a direct action 
mainly on osteoblasts and osteocytes[17]. Because of the 
inhibitory effect of prednisolone on osteoblast proliferation 
and viability, we asked whether prednisolone might 
inhibit also osteosarcoma cell proliferation. Indeed, the 
outcome of antineoplastic therapies in osteosarcoma 
is not satisfactory and the quest for novel treatments 
continues. Here, we investigated the effects of pre-
dnisolone on two human osteoblastic osteosarcoma cell 
lines that reveal a different degree of differentiation, 
i.e., SaOS2 and U2OS[8]. We found that SaOS2 are 
Prednisolone induces nitric oxide release in SaOS2
Because of the role of nitric oxide (NO) in bone home-
ostasis[13], we evaluated whether prednisolone affected
NOS activity. After 24, 48 and 96 h of culture in various 
concentrations of prednisolone, we found that NOS 
activity was higher in SaOS2 treated with the gluco-
corticoid as detected by Griess assay (Figure 3A), while 
no increase of NO was detected in U2OS (Figure 3B).
Since iNOS and eNOS were described in cultured 
osteoblast-like cells from various species[14], we evaluated 
the amounts of these enzymes by western blot in 
SaOS2. The phosphorylation of p-eNOSSer1177 was also 
investigated because it enhances enzyme activity[11]. 
After 12 and 24 h exposure to prednisolone (6 µmol/L), 
iNOS was up-regulated (Figure 3C), while the amounts of 
total eNOS and p-eNOSSer1177 remained almost unvaried. 
 
Inhibition of iNOS activity rescues SaOS2 cell 
proliferation
To study whether an increased activity of NOS was 
responsible for SaOS2 growth retardation by pred-
nisolone, the cells were cultured in medium containing 
various concentrations of prednisolone in the presence 
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Figure 3  Prednisolone increases the release of nitric oxide in SaOS2. A: SaOS2 were cultured in the presence of different concentrations of prednisolone. 
Nitric oxide was measured after 24, 48 and 96 h. Results are expressed as the mean ± SD of four different experiments (aP < 0.05, bP < 0.01, dP < 0.001); B: U2OS 
cells were processed as described in (A). No statistical significance was achieved; C: SaOS2 cells were exposed to prednisolone for 12 and 24 h and then lysed. 80 
µg of protein extracts were loaded on SDS-PAGE. Western blots using specific antibodies against iNOS, eNOS, p-eNOS-P-Ser1177 were performed. Actin shows 
that equal amounts of protein were loaded per lane. The figure shows a representative blot; D: The histogram shows the quantitative evaluation of NOS/actin ratio 
by densitometry. Results are expressed as the mean ± SD of three separate experiments (bP < 0.01). CTR: Control; iNOS: Inducible nitric oxide synthase; eNOS: 
Endothelial nitric oxide synthase; Prd: Prednisolone.
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activity. 
It is noteworthy that prednisolone does not induce NO 
in U2OS and this might account for the different behavior 
of the two cell lines. It is noteworthy that NO impairs 
also U2OS proliferation as shown in a study that links 
the increased activity of iNOS and the detrimental effects 
of benzyl isothiocyanate and phenethyl isothiocyanate 
on these cells[21]. It is also possible that the different 
response of SaOS2 and U2OS to prednisolone is due 
to the many differences of their proteomic profile[9,22]. 
Alternatively, since the glucocorticoid receptor gene 
generates several splice and translation protein variants 
that lead to different genomic and non genomic effects, 
the different response of U2OS and SaOS2 might result 
from the expression of various isoforms of glucocorticoid 
receptors. 
We have previously shown that increased iNOS 
activity mediates SaOS2 growth inhibition by low magne-
sium[11]. Therefore NO is emerging as a relevant signaling 
molecule to control SaOS2 cell proliferation. 
Our results indicate that prednisolone impairs SaOS2 
cell proliferation through the upregulation of iNOS and 
consequent induction of NO release.
COMMENTS
Background
Glucocorticoids control the growth and differentiation of osteoblasts and bone 
mesenchymal stem cells. Little is known about the effects of glucocorticoids 
on osteosarcoma cells. The authors therefore evaluated the response to 
prednisolone of two human osteosarcoma cell lines, i.e., SaOS2, which show a 
mature phenotype, and U2OS, which are rather undifferentiated.
Research frontiers
Prednisolone inhibited SaOS2 cell growth through the induction of inducible 
nitric oxide (NO) synthase with consequent increase of NO production. No 
effects were observed in U2OS.
Innovations and breakthroughs
NO is emerging as a relevant signaling molecule to control SaOS2 cell 
proliferation under different experimental conditions. This result also highlights 
the different sensitivity to prednisolone of osteosarcoma cells with different 
degree of differentiation.
 COMMENTS
growth inhibited by prednisolone while U2OS are not. 
We therefore investigated the mechanisms underlying 
prednisolone inhibition of SaOS2 cell growth, which also 
means to understand why U2OS are far less sensitive 
to the drug. Glucocorticoids are known to alter redox 
balance. Indeed, the administration of prednisolone 
to mice increased ROS production in the bone and 
dexamethasone had similar effects on osteoblastic 
cells in vitro[12]. Moreover, prednisolone enhanced the 
formation of superoxide by augmenting NADPH oxidase 
activity in pulmonary endothelial cells[18]. We found no 
significant induction of ROS production in prednisolone-
treated SaOS2. In agreement with this result, two anti-
oxidants with different mechanisms of action have no 
effect in preventing SaOS2 cell growth inhibition by 
prednisolone. 
Also NO has a role in bone homeostasis. Low NO 
levels stimulate, while high concentrations inhibit bone 
formation. It is eNOS, constitutively expressed in the 
bone, that is implicated in maintaining the basal levels 
of NO[19]. Accordingly, eNOS-/- mice show defective 
bone formation and are osteopenic[11]. Also iNOS null 
mice show imbalances in bone osteogenesis and abnor-
malities in bone healing[11]. It is interesting to note 
that iNOS pathway is crucial in bone resorption upon 
inflammatory stimuli and also mediates the negative 
effects of estrogen depletion on bones[20]. Indeed, once 
activated, iNOS is capable of generating high levels of 
NO locally for many hours. It should be recalled that NO 
is also an inducer of stress signaling, owing to its ability 
to damage proteins and DNA. We here show that SaOS2 
exposed to prednisolone upregulate iNOS and, because 
of this, produce higher amounts of NO than untreated 
cells. Indeed, pharmacological inhibition of iNOS reduced 
NO release to basal levels and restored the normal 
proliferation rate. The mechanisms implicated in iNOS 
induction are still a matter of investigation. It is known 
that iNOS is regulated through the activation of several 
signaling pathways among which NF-κB and MAPK. 
We can rule out a role of NF-κB, since glucocorticoids 
suppress NF-κB activity. More studies are necessary to 
reveal the pathways responsible for the increase of iNOS 
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Figure 4  Pharmacological inhibition of inducible nitric oxide synthase rescues SaOS2 cell growth. A: SaOS2 were treated with prednisolone in the presence 
or in the absence of L-NIL (100 μmol/L). Nitric oxide was measured as described (bP < 0.01); B: Viable SaOS2 cells were counted after 4 d in the presence of different 
concentrations of prednisolone with or without L-NIL (bP < 0.01). CTR: Control; L-NIL: l-N6-(iminoethyl)-lysine-HCl.
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Applications
More than one cell line should be used when in vitro experiments are 
performed to test the response to various compounds. The possibility of using 
glucocorticoids in animal models of osteosarcoma should be fostered. 
Peer-review
The manuscript by Cazzaniga et al analyses the effects of prednisolone on two 
different osteosarcoma cell lines. The data are novel and the experiments have 
been competently performed.
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